Celularity (CELU) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lipocine (LPCN) has outperformed Celularity (CELU) over the past year, losing 53.2% versus a loss of 73.5%. Over five years, LPCN leads with a -92.3% price change compared with -99.3% for CELU. Lipocine is the larger company by market cap ($16.4 million vs $15.0 million), about 1.1 times the size, while Celularity is growing revenue faster (-51.0% vs -82.3%).
Celularity converts more of its revenue into profit, with a net margin of -345.4% versus -487.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | LPCN |
|---|---|---|
| Share price | $0.463 | $1.48 |
| Market cap | $15.02M | $16.39M |
| 1-day change | -1.05% | -1.33% |
| YTD return | -58.29% | -81.57% |
| 1-year return | -73.54% | -53.16% |
| 5-year return | -99.31% | -92.30% |
| EPS (TTM) | $-1.69 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | $1.98M |
| Revenue growth (YoY) | -51.03% | -82.35% |
| Net income (latest FY) | $-91.72M | $-9.63M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | -524.69% |
| Net margin | -345.45% | -487.06% |
| 52-week high | $2.55 | $12.37 |
| 52-week low | $0.42 | $1.36 |
| Distance from 52-week high | -81.84% | -88.04% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +237.84% |
| Average volume | 3.95M | 1.84M |
| Shares outstanding | 32.45M | 11.07M |
| Employees | 115 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed CELU by 20.4 percentage points over the past year.
- Celularity is more profitable, keeping -345.4 cents of every revenue dollar as net income versus -487.1 cents for Lipocine.
- Celularity grew revenue faster in its latest fiscal year (-51.03% vs -82.35%).
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
CELU vs LPCN FAQ
Which is bigger, Celularity or Lipocine?
Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.02M for Celularity (CELU).
Which stock has performed better over the past year, CELU or LPCN?
LPCN returned -53.16% over the past 12 months, compared with -73.54% for CELU (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.